Study to Investigate the Safety & Efficacy of BRII-835 & BRII-179

See also
Status	Clinical Trial	Phase
Completed	`NCT03272009` - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects	Phase 1
Recruiting	`NCT01456312` - HBsAg Related Response Guided Therapy	Phase 4
Terminated	`NCT01886300` - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam	N/A
Completed	`NCT00962975` - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies	Phase 1
Completed	`NCT01023230` - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B	Phase 1
Completed	`NCT00536263` - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)	Phase 3
Terminated	`NCT00460850` - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.	Phase 4
Completed	`NCT03681132` - The Norwegian Nucleoside Analogue Stop Study	Phase 4
Active, not recruiting	`NCT05473806` - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes	Phase 4
Withdrawn	`NCT01179594` - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.	Phase 4
Recruiting	`NCT05057065` - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed	`NCT04439539` - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection	Phase 2
Withdrawn	`NCT03125213` - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects	Phase 2
Active, not recruiting	`NCT04782375` - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B	Phase 4
Withdrawn	`NCT05550519` - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment	Early Phase 1
Completed	`NCT02693652` - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine	Phase 1/Phase 2
Enrolling by invitation	`NCT04160897` - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting	`NCT02588937` - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients	Phase 4
Completed	`NCT02612506` - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers	Phase 1
Recruiting	`NCT02327416` - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)	Phase 3

NCT number	NCT04749368
Study type	Interventional
Source	Brii Biosciences Limited
Contact
Status	Completed
Phase	Phase 2
Start date	April 12, 2021
Completion date	July 4, 2023

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms